

# Artificial Intelligence–Driven Digital Twins, Multi-Omics and Precision Hepatitis Care: Emerging Innovations, Challenges, and Future Perspectives

Kalyani Chande<sup>1\*</sup>, Rishabh P. Soni<sup>1</sup>, Riddhi S Petkar<sup>1</sup>, Raj A. Patil<sup>1</sup>

<sup>1</sup>Assistant Professor, Dr. D. Y. Patil College of Pharmacy, Akurdi, Pune 411044, Maharashtra, India.

Students, Dr. D. Y. Patil College of Pharmacy, Akurdi, Pune 411044, Maharashtra, India.

**Corresponding author:** Kalyanichande17@gmail.com

**Doi:** <https://doi.org/10.5281/zenodo.22685785>

Received: 30 July 2026

Accepted: 23 August 2026

## ABSTRACT

Due to persistent diagnostic delays, varied disease progression, and unpredictable therapy responses, viral hepatitis remains a major worldwide health concern despite advances in antiviral medication and vaccine. Precision hepatology is a viable strategy for overcoming these limitations through tailored, data-driven clinical care. The confluence of digital twin systems, multi-omics technologies, and artificial intelligence (AI) as an integrated ecosystem for precision hepatitis therapy is covered in detail in this research. Multi-omics systems that offer comprehensive molecular characterisation of disease heterogeneity and help identify biomarkers include genomics, transcriptomics, epigenomics, proteomics, metabolomics, microbiomics, and radiomics. AI techniques enhance prognostic assessment, fibrosis staging, hepatocellular carcinoma risk prediction, early identification, and customised treatment selection. These techniques include explainable AI, generative AI, machine learning, and deep learning. Digital twin technologies enable dynamic virtual patient modelling, therapy simulation, real-time sickness monitoring, and predictive clinical decision support. The study also highlights novel computational techniques including knowledge graphs, graph neural networks, federated learning, and multimodal data integration that facilitate translational precision hepatology. A critical analysis is conducted of present and future viewpoints regarding data standardisation, interoperability, algorithmic bias, privacy, regulatory validation, and ethical governance. The combination of AI, multi-omics, and digital twins promises a breakthrough paradigm for predictive, preventative, personalised, and participative (P4) hepatitis therapy with the potential to greatly improve clinical outcomes and accelerate precision medicine.

**Keywords:** Hepatocellular carcinoma; biomarkers; machine learning; precision hepatology; artificial intelligence; multi-omics; digital twins; precision medicine; viral hepatitis; personalised healthcare.

## 1. INTRODUCTION

Viral hepatitis remains a major global public health concern despite tremendous progress in vaccination, antiviral treatment, and disease surveillance [1,2]. Over 300 million individuals have chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, which results in approximately 1.3 million deaths annually, primarily from cirrhosis and hepatocellular carcinoma (HCC), according to the World Health Organization (WHO) [1]. Therefore, the WHO aims to eliminate viral hepatitis as a threat to public health by 2030. But progress is still hampered by the rising incidence of advanced liver disease, regional healthcare disparities, delayed diagnosis, and limited access to screening and treatment [2, 3]. The need for more effective and long-lasting management strategies is highlighted by the fact that, in addition to its clinical effects, viral hepatitis has a substantial financial impact due to medical costs, lost productivity, and a reduced quality of life [4,5].

Even while modern antiviral medicines have significantly improved patient outcomes, clinical management still mostly relies on standardised diagnostic and therapeutic approaches that typically overlook significant inter-individual variation [6,7]. Patients with similar viral loads or biochemical profiles frequently exhibit differences in immune responses, fibrosis progression, therapeutic efficacy, and HCC risk due to complex interactions between host genetics, viral diversity, epigenetic regulation, metabolism, environmental exposures, and lifestyle factors [8–10]. These limitations have accelerated the transition from traditional management to precision hepatology, which aims to provide customised, biomarker-driven care based on each patient's unique biological characteristics [6,11].

Recent advancements in high-throughput multi-omics technologies, including genomics, transcriptomics, epigenomics, proteomics, metabolomics, microbiomics, and radiomics, have greatly expanded our knowledge of viral pathogenesis and host responses in addition to making it easier to identify biomarkers and improve patient stratification [12–15]. Artificial intelligence (AI), which includes machine learning, deep learning, explainable AI, and large language models, has simultaneously developed into a powerful tool for analysing complex multidimensional datasets to support early diagnosis, fibrosis staging, HCC risk prediction, treatment selection, and prognostic assessment [16–20]. Digital twins improve current technologies by creating dynamic virtual patient models that enable customised therapeutic decision-making and disease progression simulation through the integration of clinical, imaging, laboratory, and multi-omics data [21–23]. Together, AI, multi-omics, and digital twins provide a complimentary technology ecosystem that can promote personalised, preventive, predictive, and participatory hepatology.

Despite the growing amount of studies on each technology, there is still a lack of an integrated understanding of their combined use in viral hepatitis [17,21,24]. Therefore, this review critically examines the complementary roles of AI, multi-omics, and digital twin technologies in precision hepatology, highlighting their current clinical applications, challenges, future prospects, and potential contribution to the achievement of global viral hepatitis elimination goals.

## 2. Multi-Omics Landscape in Hepatitis

By providing a comprehensive understanding of disease mechanisms at multiple biological levels, the introduction of multi-omics technology has transformed the research of hepatitis. Unlike conventional diagnosis based on

biochemical markers, viral serology, and histology, multi-omics integrates genomic, transcriptomic, epigenomic, proteomic, metabolomic, microbiome, and imaging data to identify disease heterogeneity and advance precision therapy. High-throughput sequencing, mass spectrometry, advanced imaging, and artificial intelligence (AI) have made it possible to identify molecular markers associated with hepatocellular carcinoma (HCC), fibrosis, cirrhosis, immunological dysregulation, and viral persistence. AI-driven computational frameworks for prognosis prediction, disease classification, biomarker identification, and personalised therapeutic decision-making further integrate heterogeneous information [25–28].




Figure 1: Multi-omics hierarchy

Table 1: Multi-omics technologies and their applications in hepatitis

| Omics platform | Key technologies    | Application in hepatitis                                                | Representative citation(s) |
|----------------|---------------------|-------------------------------------------------------------------------|----------------------------|
| Genomics       | NGS, WGS, WES, GWAS | Disease susceptibility, viral evolution, antiviral response prediction. | [2,5]                      |

|                        |                                                           |                                                                                |         |
|------------------------|-----------------------------------------------------------|--------------------------------------------------------------------------------|---------|
| Transcriptomics        | RNA-seq, scRNA-seq, spatial transcriptomics               | Gene expression profiling, immune pathway analysis, patient stratification.    | [2,4,6] |
| Epigenomics            | DNA methylation profiling, ChIP-seq, ATAC-seq             | Fibrosis progression, viral persistence, HCC risk assessment.                  | [5,7]   |
| Proteomics             | LC-MS/MS, MALDI-TOF, TMT labeling                         | Inflammation markers, fibrosis staging, treatment monitoring.                  | [1,5]   |
| Metabolomics           | NMR, GC-MS, LC-MS                                         | Early disease detection and therapy response evaluation.                       | [1,3]   |
| Microbiome             | 16S rRNA sequencing, shotgun metagenomics                 | Gut-liver axis analysis and disease severity prediction.                       | [1,4]   |
| Radiomics              | CT, MRI, ultrasound, elastography                         | Non-invasive fibrosis staging and early HCC detection.                         | [2,4]   |
| Integrated multi-omics | Similarity network fusion, GNNs, multimodal deep learning | Biomarker discovery, disease subtype identification, digital twin development. | [2–4]   |

## 2.1 Genetics

Genomics provides insight into treatment response, viral evolution, and disease risk by examining the complete genetic landscape of the host and hepatitis viruses. Technologies such as next-generation sequencing (NGS), whole-genome sequencing (WGS), whole-exome sequencing (WES), targeted sequencing, and genome-wide association studies (GWAS) have improved our understanding of the pathophysiology of hepatitis. Host genetic variants in HLA-DP, IFNL3 (IL28B), MICA, PNPLA3, and TM6SF2 are associated with HCC susceptibility, fibrosis development, and viral clearance. Genomic sequencing also detects HBV DNA integration and viral

mutations related to hepatocarcinogenesis, whereas AI-assisted genomic analysis improves antiviral response prediction, therapeutic target selection, and harmful variant prioritisation [26, 29].

## **2.2 Transcriptomics**

Transcriptomics studies dynamic changes in gene expression as hepatitis progresses. The expression of messenger RNA (mRNA), microRNA (miRNA), long non-coding RNA (lncRNA), and circular RNA is analyzed by technologies like RNA sequencing (RNA-seq), single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, and microarrays. While single-cell transcriptomics has shown cellular heterogeneity among hepatocytes, Kupffer cells, hepatic stellate cells, and infiltrating immune cells, these methods have identified dysregulated interferon signaling, cytokine networks, immune checkpoint molecules, and fibrosis-related genes in chronic HBV and HCV infections. For better patient stratification and prognosis prediction, disease-specific transcriptional signatures are further identified by AI-driven neural networks, network analysis, and clustering algorithms [26,28,30].

## **2.3 Epigenomics**

Without changing the DNA sequence, epigenomics studies heritable variations in gene expression. Epigenetic changes linked to chronic inflammation, fibrosis, and hepatocellular carcinoma (HCC) have been found using methods such DNA methylation profiling, ChIP-seq, ATAC-seq, bisulfite sequencing, and histone modification analysis. Hepatocarcinogenesis and viral persistence are encouraged by aberrant DNA methylation and histone acetylation caused by persistent HBV infection. Early diagnosis, illness progression prediction, and the identification of high-risk patients and epigenetic therapeutic targets are all made easier by AI-driven integration of methylation patterns with clinical data [29, 31].

## **2.4 Proteomics**

Global protein expression, post-translational changes, and protein–protein interactions related to liver function and disease progression are all examined by proteomics. Tandem mass tag (TMT) labeling, MALDI-TOF, LC-MS/MS, and two-dimensional gel electrophoresis are important analytical platforms. In chronic hepatitis and hepatocellular carcinoma (HCC), proteomic investigations have shown biomarkers linked to oxidative stress, coagulation, inflammation, extracellular matrix remodeling, and complement activation. Deep learning and predictive modeling are used in AI-assisted proteomics to enhance fibrosis staging, illness classification, and treatment tracking [25,29].

## **2.5 Metabolomics**

Metabolomics uses nuclear magnetic resonance (NMR), gas chromatography-mass spectrometry (GC-MS), liquid chromatography-mass spectrometry (LC-MS), and capillary electrophoresis-mass spectrometry to examine low-molecular-weight metabolites that represent host-virus interactions. Hepatitis development is tightly linked to changes in oxidative stress, tricarboxylic acid cycle intermediates, amino acid, bile acid, and lipid metabolism. While AI-driven statistical modeling and machine learning enhance metabolite classification and forecast accuracy, these metabolic signatures function as sensitive biomarkers for early diagnosis and treatment response [25, 27].

## 2.6 Microbiome

The gut-liver axis is highlighted by microbiomics as a crucial regulator of the pathophysiology of hepatitis. Gut microbial dysbiosis linked to chronic liver disease has been identified using high-throughput 16S rRNA sequencing, shotgun metagenomics, metatranscriptomics, and metaproteomics. Hepatic inflammation and bacterial translocation are encouraged by increased intestinal permeability, which can lead to cirrhosis, fibrosis, hepatic encephalopathy, and hepatocellular carcinoma (HCC). Microbiome-based treatments, such as probiotics, prebiotics, and fecal microbiota transplantation, are supported by AI-assisted microbiome research, which finds microbial patterns predictive of illness severity [25,28].

## 2.7 Radiomics

Radiomics transforms traditional medical images into high-dimensional quantitative data that describes the texture, shape, vascularity, fibrosis, and heterogeneity of tissue. The main imaging modalities include computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and transient elastography. Accurate non-invasive fibrosis staging, portal hypertension evaluation, therapy monitoring, and early hepatocellular carcinoma (HCC) identification are all made possible by deep learning-based radiomics. By combining radiomic characteristics with genetic biomarkers, diagnostic precision is further improved and the need for liver biopsies is decreased [26, 28].

## 2.8 Integration of Multi-Omics

Precision hepatology relies heavily on integrated multi-omics, which allows for the simultaneous investigation of genomic, transcriptomic, proteomic, metabolomic, microbiome, radiomic, and clinical data. Disease subtyping, fibrosis prediction, antiviral response evaluation, and digital twin generation are made easier by computational techniques like similarity network fusion, Bayesian integration, graph neural networks, transformer architectures, and multimodal deep learning. Federated learning protects patient privacy while enhancing model stability and clinical translation through safe multicenter data integration [26–28].

## 2.9 Finding Biomarkers

Hepatitis biomarkers, such as host genetic variations, circulating microRNAs, extracellular vesicles, DNA methylation profiles, plasma proteins, metabolic signatures, microbial taxa, and radiomic features, have been found more quickly thanks to multi-omics integration. Strong biomarker panels with increased sensitivity and specificity are found using AI-driven techniques such feature selection, explainable AI (XAI), ensemble learning, and deep neural networks. Early diagnosis, customized antiviral treatment, fibrosis prediction, HCC surveillance, and precision medicine are all supported by these integrated biomarkers. Proactive, customized hepatitis treatment is anticipated to be transformed by future integration with digital twin technologies and real-time clinical data [26–28].

## 3. Artificial Intelligence for Accurate Hepatitis Treatment

Precision hepatology is largely driven by artificial intelligence (AI), which makes data-driven diagnosis, prognosis, therapeutic decision-making, and individualized care possible. AI finds intricate biological patterns that go beyond traditional statistical techniques by combining wearable health data, radiographic imaging, digital

pathology, multi-omics datasets, and electronic health records (EHRs). Early disease identification, fibrosis staging, cirrhosis and hepatocellular carcinoma (HCC) prediction, antiviral medication optimization, and individualized prognosis are all supported. By using patient-specific data to model disease development and treatment outcomes, AI also serves as the computational foundation for digital twins, enhancing evidence-based care and healthcare efficiency [32–37].




**Figure 2: Computational framework for AI and machine learning (from data acquisition to clinical implementation)**

**Table 2: AI algorithms and clinical applications in hepatitis**

| AI approach      | Representative algorithms                        | Clinical application in hepatitis                             | Representative citation(s) |
|------------------|--------------------------------------------------|---------------------------------------------------------------|----------------------------|
| Machine learning | Logistic regression, SVM, Random Forest, XGBoost | Disease classification, fibrosis staging, outcome prediction. | [32,33,36,37]              |
| Deep learning    | CNNs, RNNs, LSTMs                                | Imaging analysis, liver segmentation, HCC detection.          | [32,34,35]                 |

|                                   |                                        |                                                                 |            |
|-----------------------------------|----------------------------------------|-----------------------------------------------------------------|------------|
| Multimodal deep learning          | Integrated neural network frameworks   | Combined analysis of imaging, omics, and clinical data.         | [32,34,39] |
| Transformer models                | Transformer architectures              | Longitudinal clinical record analysis and prognosis prediction. | [33–35]    |
| Generative AI / LLMs              | Large language models                  | Clinical documentation, literature synthesis, decision support. | [38,41,42] |
| Explainable AI                    | Feature attribution methods            | Interpretation of predictive models and biomarker importance.   | [32,36]    |
| Clinical decision support systems | AI-integrated CDSS                     | Treatment selection, adverse event prediction, monitoring.      | [32,33,42] |
| Predictive analytics              | Ensemble learning, longitudinal models | Cirrhosis progression, HCC risk, antiviral response prediction. | [32–37]    |




**Figure 3: AI applications**

### 3.1 Automated Learning

Without the need for explicit programming, machine learning (ML) finds patterns in organized and semi-structured data. While unsupervised techniques like principal component analysis (PCA), k-means, and hierarchical clustering allow patient stratification and molecular subtype identification using clinical and multi-omics data, supervised algorithms like logistic regression, support vector machines (SVM), random forests (RF), decision trees, gradient boosting machines (GBM), and extreme gradient boosting (XGBoost) are frequently used for disease classification, fibrosis staging, and outcome prediction [32,33,36]. ML models produce personalized risk estimates by combining liver function tests, viral load, demographics, genetic polymorphisms, inflammatory biomarkers, elastography, and imaging characteristics. Evidence-based precision hepatology, prediction robustness, and diagnostic accuracy are further enhanced by feature selection and ensemble learning [32, 33, 37].

### 3.2 In-depth Education

Using multilayer neural networks, deep learning, a subset of machine learning, automatically derives hierarchical features from clinical data, medical pictures, genetic sequences, and histopathology, doing away with the need for manual feature engineering [32,34,35]. While recurrent neural networks (RNNs), long short-term memory (LSTM) networks, and transformer-based models examine longitudinal clinical data, laboratory trends, and treatment histories to predict disease progression and therapeutic response, convolutional neural networks (CNNs) achieve high accuracy in liver segmentation, cirrhosis detection, fibrosis staging, and early hepatocellular carcinoma diagnosis using CT, MRI, ultrasound, transient elastography, and digital pathology [33–35]. Radiomics, genomics, transcriptomics, proteomics, metabolomics, microbiome profiles, and electronic health records are all integrated into unified predictive models by recent multimodal DL. Transfer learning and self-supervised learning further enhance accuracy and generalizability while lowering reliance on sizable annotated datasets [32,34,39].

### 3.3 Large Language Models and Generative AI

Clinical documentation, medical data synthesis, patient record summarization, literature reviews, evidence-based decision-making, and digital twin construction in hepatology are all supported by generative AI, which is driven

by Large Language Models (LLMs) and transformer architectures [38,41,42]. LLMs create thorough clinical summaries and support disease trajectory simulation, differential diagnosis, clinical trial identification, guideline-based research, literature synthesis, and synthetic patient data generation by combining pathology, imaging, laboratory, clinical, and genomic data [38,41]. To improve clinical insights, multimodal LLMs further integrate pathology slides, laboratory findings, radiographic pictures, and omics data. However, for safe and dependable usage in precision hepatology, issues including algorithmic bias, limited explainability, hallucinations, privacy, cybersecurity, and regulatory compliance need stringent clinical validation and ongoing human oversight [38–42].

### **3.4 Systems for Clinical Decision Support**

In order to deliver real-time diagnosis and treatment suggestions, Clinical Decision Support Systems (CDSS) combine artificial intelligence (AI) with electronic health data. To provide individualized, evidence-based clinical guidance, AI-enabled CDSS examines imaging, lab results, medication history, viral indicators, genetic information, and patient demographics [32,33,42].

High-risk patients are identified, antiviral therapy is suggested, treatment duration is optimized, adverse drug reactions are predicted, and treatment response is tracked using these systems. Proactive disease management and ongoing patient assessment are supported by integration with wearable technology and remote monitoring. In order to further improve tailored care and decrease trial-and-error therapy, future CDSS linked with digital twin technology will model individualized illness progression under various treatment regimens [32, 39, 42].

### **3.5 Use in Clinical Settings**

Through the discovery of modest molecular, biochemical, and imaging abnormalities prior to the onset of symptoms, artificial intelligence (AI) has shown great clinical utility throughout the hepatitis care continuum [32–37]. AI lowers the need for liver biopsies, enhances imaging interpretation, and minimizes interobserver variability by combining elastography, laboratory biomarkers, radiomics, and histology to accurately grade liver fibrosis [34,35,39]. Despite the fact that longitudinal machine learning models enhance early risk assessment for hepatic decompensation and cirrhosis, their regular clinical adoption is still constrained by a lack of prospective multicenter validation [32, 33, 36]. AI integrates genetic, transcriptomic, imaging, and clinical data to predict hepatocellular carcinoma (HCC); nonetheless, prediction ability varies across patient populations and needs wider validation [34,35,37]. Furthermore, AI predicts antiviral resistance, treatment failure, and sustained virological response to improve efficacy, guide timely treatment modifications, lower adverse effects and healthcare costs, and improve long-term outcomes [32,33,36,37]. AI optimizes antiviral therapy by incorporating viral genotype, host genetics, liver function, comorbidities, drug interactions, and treatment history.

## **4. Using Digital Twins to Treat Hepatitis**

A new precision medicine technique called "digital twin technology" uses real-time clinical, molecular, physiological, and environmental data to construct a dynamic virtual depiction of a person. Digital twins, in contrast to traditional prediction models, continually model the course of a disease, forecast treatment results, and assess therapeutic approaches prior to clinical application. For chronic hepatitis, liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC), digital twins enable personalized monitoring, risk prediction, and treatment optimization by combining artificial intelligence (AI), multi-omics, radiological imaging, electronic health records

(EHRs), wearable sensor data, and lifestyle information. Hepatology is still in its infancy, but developments in AI, cloud computing, IoMT, and high-performance computing are speeding up its clinical translation [43–47].




**Figure 4: Integrated AI + Multi-Omics + Digital Twin Ecosystem**

#### 4.1 Concept

In order to model physiological processes and forecast health outcomes, a digital twin is a dynamic virtual depiction of a human that continually integrates multimodal biological and clinical data [43, 45]. Digital twins, in contrast to static models, change during the course of a patient's care by adding genomic information, treatment history, imaging, test findings, and real-time physiological monitoring [43, 44]. They mimic the course of hepatitis from viral infection to cirrhosis, fibrosis, and hepatocellular carcinoma (HCC), forecast the response to antiviral therapy, track the recurrence of the illness, and facilitate the virtual assessment of therapeutic approaches to assist precision medicine [45,46].

#### 4.2 Design

The physical patient, data gathering systems, computational intelligence, and clinical visualization [43,45] are the four interconnected layers that make up a digital twin. AI preprocesses and harmonizes heterogeneous datasets in secure cloud-based platforms that combine patient data from wearable sensors, mobile health applications, imaging, histopathology, laboratory testing, and electronic health records (EHRs) [43,44]. The virtual twin is constantly updated to represent the course of the disease by machine learning, deep learning, probabilistic simulations, and mechanistic models. In order to facilitate evidence-based decision-making, interactive

dashboards then offer clinicians disease trajectories, treatment simulations, anticipated outcomes, and customized risk assessments [45,47].

#### **4.3 Data Integration**

Multimodal patient data from various sources must be seamlessly integrated for digital twins to function [43, 44]. A comprehensive digital depiction of liver health is produced by AI-powered frameworks that integrate genomic, transcriptomic, epigenomic, proteomic, metabolomic, microbiome, radiomic, histopathological, and clinical data [44, 45]. While wearable technology continuously monitors physiological factors like heart rate, metabolic status, sleep, and physical activity, electronic health records offer longitudinal clinical information. Real-time data synchronization while protecting patient privacy is made possible by cloud computing, federated learning, interoperability standards, and safe data-sharing frameworks [43,45,47]. Digital twins can continuously reflect the course of a disease and the effectiveness of treatment thanks to this integrated approach.

#### **4.4 Predictive Models Driven by AI**

The foundation of digital twin technology is artificial intelligence (AI), which analyzes multidimensional datasets and forecasts clinical outcomes utilizing machine learning, deep learning, reinforcement learning, Bayesian networks, graph neural networks, and transformer-based models [43, 45]. AI forecasts cirrhosis, hepatocellular carcinoma (HCC) risk, fibrosis progression, antiviral therapy response, and long-term outcomes in hepatitis. While AI-driven simulations enable physicians to assess therapy approaches and maximize patient care prior to clinical deployment, continuous learning allows digital twins to update predictions as fresh imaging, laboratory, and treatment data become available [45–47].

#### **4.5 Customized Illness Modeling**

By simulating individual disease trajectories using patient-specific biological data and computer models, digital twins allow for individualized disease modeling [43,46]. They forecast the course of chronic hepatitis, the development of fibrosis, the risk of hepatocellular carcinoma (HCC), and the response to antiviral therapy in various clinical situations [45–47]. These virtual models support individualized treatment planning, collaborative decision-making, and effective use of healthcare resources by enabling clinicians to assess alternative therapies, lifestyle interventions, surveillance strategies, and combination treatments without putting patients at needless risk [43,46]. These forecasts are further improved through ongoing integration of real-time patient data, which sets digital twins apart from traditional clinical prediction algorithms.

#### **4.6 Present-Day Clinical Uses**

Digital twins are still in their infancy in hepatology, with no prospective clinical validation, despite proof-of-concept studies showing significant promise [43,44]. Predicting the course of liver fibrosis, optimizing antiviral medication, evaluating the risk of hepatocellular carcinoma (HCC), organizing liver transplantation, tracking recovery after treatment, and facilitating virtual clinical trials are some of the current applications [45–47]. Personalized surveillance and patient stratification are further enhanced by integration with radiomics and multi-omics. Precision hepatology and digital healthcare are expected to rely heavily on digital twins, and their successful use in critical care, cardiovascular medicine, and oncology provides a strong foundation for future hepatology applications [44,46,47].

#### **4.7 Restrictions**

There are several challenges to overcome, such as data heterogeneity, a lack of standardised validation frameworks, computational complexity, limited longitudinal multi-omics datasets, high infrastructure costs, and poor interoperability, despite the potential revolutionary potential of digital twins in hepatitis [43–45]. Algorithmic bias, restricted model transparency, cybersecurity, patient privacy, regulatory approval, and moral dilemmas related to AI-assisted decision-making are further challenges [45,47]. Additionally, there is no prospective clinical validation in hepatology, and the majority of applications are still in the proof-of-concept stage. Standardised data-sharing, explainable AI, international collaboration, and robust regulatory frameworks are necessary to overcome these challenges in order for clinical deployment to be successful [43,45,47].

#### **5. Integrated Digital Twin, Multi-Omics, and AI Ecosystem**

Artificial intelligence (AI), digital twins, and multi-omics technology are revolutionising precision hepatology. Even while each of these technologies improves hepatitis diagnosis and treatment on its own, when coupled, they provide an ever-evolving ecosystem that generates customised clinical insights from a variety of patient data [48–51]. This approach combines genetic, transcriptomic, epigenomic, proteomic, metabolomic, microbiome, radiomic, and clinical data into a single computational model, in contrast to traditional healthcare models that depend on discrete laboratory or imaging results [48–50]. While digital twins function as dynamic virtual patient models that mimic illness progression and treatment outcomes, artificial intelligence (AI) serves as the analytical engine to find significant biological patterns [49–52]. When combined, they provide proactive, predictive, preventative, and personalized (P4) healthcare, which is a significant improvement in the treatment of precision hepatitis [48,50,51,54].




**Figure 5: Integrated AI + Multi-Omics + Digital Twin Ecosystem**

### 5.1 Integration of Multimodal Data

Multimodal data integration is the cornerstone of the AI–multi-omics–digital twin ecosystem in precision hepatology [48–50]. Integrating several datasets yields a more thorough knowledge than any single data source because hepatitis is regulated by host genetics, viral factors, immunological responses, metabolism, environmental exposures, and treatment interventions [48, 49]. To improve illness characterisation and individualized care, contemporary computational platforms integrate genomic, transcriptomic, epigenetic, proteomic, metabolomic, microbiome, radiomic, histopathology, and longitudinal clinical data into cohesive analytical frameworks [48–51]. Secure data exchange and harmonization between institutions are made possible by cloud computing, federated learning, IoMT devices, interoperable electronic health records, and standardized healthcare data models [49–52]. More sophisticated preprocessing methods enhance data quality even more, facilitating improved clinical decision-making, disease monitoring, and diagnostic accuracy [48–51].

### 5.2 Graphs of Knowledge

By depicting genes, proteins, metabolites, signaling pathways, diseases, medications, biomarkers, and clinical symptoms as interconnected biological networks rather than discrete records, knowledge graphs provide a novel paradigm for integrating disparate biomedical data [51–53]. AI can discover hitherto unidentified connections

between biological pathways, therapeutic targets, and disease mechanisms thanks to this network-based method [51–53].

Knowledge graphs enable biomarker identification, drug repurposing, adverse event prediction, and mechanistic interpretation of AI-generated results in hepatitis research by integrating viral biology, host immune responses, multi-omics, imaging, pharmacological, and clinical data into a unified framework [50–54]. By discovering intricate connections between interrelated biological factors, graph neural networks (GNNs) enhance clinical decision-making, speed up translational research, and further increase predictive performance [52–54].

### **5.3 Analytical Predictions**

The computational foundation of the AI–multi-omics–digital twin ecosystem is predictive analytics, which converts multidimensional patient data into insights that may be used in therapeutic settings [49–54]. To forecast illness development, treatment response, and clinical outcomes, machine learning, deep learning, Bayesian inference, reinforcement learning, transformer models, and graph neural networks continuously evaluate changing patient data [49,51,54]. AI captures intricate biological relationships across several molecular layers and adjusts to new data, in contrast to conventional statistical methods [50–54]. By identifying high-risk patients, predictive analytics facilitates tailored treatment planning; yet, its dependability is dependent on high-quality, externally validated datasets [49–54].

### **5.4 Tailored Clinical Choices**

By substituting patient-specific computational models that take into account genetic background, viral characteristics, immune profile, metabolic status, imaging features, lifestyle factors, and therapeutic history for uniform treatment strategies, the integration of AI, multi-omics, and digital twin technologies allows for personalized healthcare decision-making [48–52]. To anticipate therapy responses, improve antiviral regimens, evaluate adverse event risks, and establish suitable surveillance intervals prior to clinical deployment, digital twins model various treatment scenarios [50–52]. In the meantime, wearable sensor data, imaging findings, laboratory results, and patient-reported outcomes are continuously integrated by AI-assisted clinical decision support systems, enabling therapy recommendations to change as the disease is managed [49,51,53]. This flexible strategy decreases healthcare costs, increases therapeutic efficacy, minimizes needless procedures, and promotes patient-centered care [50–54].

### **5.5 Hepatology with Translational Precision**

By connecting biological discoveries with clinical practice, the combination of AI, multi-omics, and digital twin technologies forms the basis of translational precision hepatology [48–54]. Biomarker validation, drug discovery, clinical trials, and tailored therapies are accelerated by multi-omics' identification of disease-associated biomarkers, AI's conversion of these data into predictive models, and digital twins' validation of treatment plans in patient-specific virtual settings [48–54]. Real-time illness surveillance is made possible by ongoing integration with wearable technology, cloud-based healthcare systems, remote monitoring, and federated learning, which also enhances model robustness and safeguards patient privacy across institutions [49,51–54]. Although their clinical utility is still mostly unproven, future integration with explainable AI, blockchain, quantum computing, and foundation models may increase predicted accuracy [48–54].

## 6. Difficulties and Prospects

The extensive application of digital twin systems, multi-omics technologies, and artificial intelligence (AI) in precision hepatitis treatment is still hampered by a number of scientific, technical, ethical, and legal issues. Robust data infrastructure, standardised computational frameworks, regulatory control, interdisciplinary collaboration, and prospective clinical validation are necessary for the successful transfer of these technologies from research settings to ordinary clinical practice. To fully realise the potential of digital healthcare and precision hepatology, these issues must be resolved [55–57].

**Table 3: Precision hepatology's present difficulties and potential**

| Domain               | Current challenge                                                   | Future opportunity                        | Representative citation(s) |
|----------------------|---------------------------------------------------------------------|-------------------------------------------|----------------------------|
| Data quality         | Heterogeneous and incomplete datasets.                              | Standardized multi-omics databases.       | [55–58]                    |
| Interoperability     | Poor integration among EHRs, omics databases, and imaging archives. | Unified data-sharing frameworks.          | [56–59]                    |
| Privacy and security | Risk of unauthorized access to sensitive patient data.              | Federated learning and secure encryption. | [58–60]                    |
| Algorithmic bias     | Limited generalizability across populations.                        | Explainable and equitable AI models.      | [55,57,60,61]              |
| Regulatory approval  | Lack of validation frameworks for adaptive AI systems.              | Harmonized regulatory standards.          | [55–57]                    |
| Clinical validation  | Insufficient prospective multicenter studies.                       | Large-scale real-world validation.        | [55–64]                    |

|                       |                                              |                                                                           |            |
|-----------------------|----------------------------------------------|---------------------------------------------------------------------------|------------|
| Infrastructure cost   | High computational and storage requirements. | Cloud-based scalable platforms.                                           | [58,60,62] |
| Emerging technologies | Early-stage implementation.                  | Foundation models, digital twin hospitals, quantum computing, blockchain. | [61–64]    |

## 7. Obstacles

Scientific, technical, ethical, and regulatory obstacles continue to restrict the clinical translation of AI, multi-omics, and digital twins. Despite sophisticated imputation techniques, heterogeneous, low-quality, non-standardized, and incomplete multi-omics, imaging, and clinical datasets increase bias and decrease model accuracy and reproducibility [55–58]. Data integration is further limited by non-standard laboratory, imaging, sequencing, and reporting procedures, as well as limited interoperability between omics databases, imaging archives, and electronic health records [56–59]. While tackling algorithmic bias and enhancing explainable AI (XAI) are crucial for clinician trust, equity, and regulatory approval, protecting patient privacy necessitates strong encryption, federated learning, cybersecurity, and ethical governance [55,57,58–61]. Because AI-driven digital twins need validation frameworks that support adaptive learning, ongoing model upgrades, and real-time clinical data integration, regulatory obstacles still exist.

## 8. Prospective Paths

Foundation models should be useful for precision hepatology in the future if they undergo thorough clinical validation and regulatory assessment [61,63]. Federated learning will protect patient privacy, improve the robustness of AI models, and allow safe cooperation between healthcare organizations [59,63]. The creation of virtual twin medical facilities. Real-time illness monitoring, early intervention, and streamlined clinical workflows will be supported by integration with wearable biosensors, Internet of Medical Things (IoMT) platforms, hospital information systems, and remote monitoring devices [58,60,62]. Digital health solutions powered by AI will improve risk assessment, illness surveillance, and healthcare planning [61–64]. Multi center validation, standardized reporting, explainable AI, ethical governance, interoperability, regulatory harmonization, and integration with quantum computing, blockchain, causal AI, knowledge graphs, and complex digital twin ecosystems are all future goals [55–64].

## CONCLUSION

The combination of digital twin, multi-omics, and artificial intelligence (AI) technologies is transforming the treatment of hepatitis by making precision hepatology possible. AI helps with diagnosis, fibrosis staging, HCC prediction, prognosis, and personalized treatment; multi-omics reveals disease heterogeneity; and digital twins model disease progression and therapeutic responses to provide predictive, preventative, personalized, and

participative (P4) care. Together, these technologies improve diagnosis, sickness monitoring, antiviral optimization, reduce the need for liver biopsies, and enable personalized treatment. Implementation obstacles include data standards, interoperability, algorithmic bias, privacy, and inadequate clinical validation.

To promote clinical use, future research should give priority to standardized datasets, explainable AI, interoperable digital twin platforms, and multicenter validation. All things considered, the combination of these technologies could lead to better diagnosis, more individualized treatment, better patient outcomes, and a decrease in the prevalence of chronic liver disease worldwide.

Future research should prioritize standardized datasets, explainable AI, interoperable digital twin systems, and multicenter validation to encourage clinical adoption. Taken together, these technologies have the potential to improve patient outcomes, diagnosis, and treatment, as well as lower the global prevalence of chronic liver disease.

## **REFERENCES**

1. World Health Organization. Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva: World Health Organization; 2024.
2. World Health Organization. Global health sector strategies on HIV, viral hepatitis and sexually transmitted infections, 2022-2030. Geneva: World Health Organization; 2022.
3. Polaris Observatory Collaborators. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. *Lancet Gastroenterol Hepatol*. 2025;10(1):56-72.
4. Cooke GS, Andrieux-Meyer I, Applegate TL, et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. *Lancet Gastroenterol Hepatol*. 2019;4(2):135-184.
5. Razavi H, Robbins S, Zeuzem S, et al. Chronic hepatitis C virus burden and associated economic impact. *J Viral Hepat*. 2023;30(4):289-300.
6. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. *J Hepatol*. 2024;81(2):340-420.
7. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C. *J Hepatol*. 2024;81(4):721-760.
8. Rehermann B, Thimme R. Insights from antiviral therapy into immune responses to hepatitis B and C virus infection. *Nat Rev Immunol*. 2019;19(10):593-608.
9. Ringehan M, McKeating JA, Protzer U. Viral hepatitis and liver cancer. *Philos Trans R Soc Lond B Biol Sci*. 2017;372(1732):20160274.
10. Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world. *J Hepatol*. 2019;70(1):151-171.
11. Duffy AG, Greten TF. Precision medicine in hepatology. *Hepatology*. 2023;78(5):1634-1646.
12. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. *Genome Biol*. 2017;18:83.

13. Subramanian I, Verma S, Kumar S, et al. Multi-omics data integration, interpretation, and its application. *Bioinform Biol Insights*. 2020;14:1177932219899051.
14. Karczewski KJ, Snyder MP. Integrative omics for health and disease. *Nat Rev Genet*. 2023;24(5):299-315.
15. Auffray C, Balling R, Barroso I, et al. Making sense of big data in health research. *Genome Med*. 2016;8:71.
16. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med*. 2019;25(1):44-56.
17. Rajkomar A, Dean J, Kohane IS. Machine learning in medicine. *N Engl J Med*. 2019;380(14):1347-1358.
18. Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare. *Nat Med*. 2019;25(1):24-29.
19. Holzinger A, Biemann C, Pattichis CS, Kell DB. What do we need to build explainable AI systems for the medical domain? *arXiv [Preprint]*. 2017:1712.09923.
20. Bommasani R, Hudson DA, Adeli E, et al. On the opportunities and risks of foundation models. *arXiv [Preprint]*. 2022:2209.08191.
21. Björnsson B, Borrebaeck C, Elander N, et al. Digital twins to personalize medicine. *Genome Med*. 2020;12:4.
22. Corral-Acero J, Margara F, Marciniak M, et al. The ‘Digital Twin’ to enable the vision of precision cardiology. *Eur Heart J*. 2020;41(48):4556-4564.
23. Hood L, Friend SH. Predictive, preventive, personalized and participatory (P4) cancer medicine. *Nat Rev Clin Oncol*. 2011;8(3):184-187.
24. Hood L, Flores M. A personal view on systems medicine and the emergence of proactive P4 medicine. *New Biotechnol*. 2022;66:97-102.
25. Xiang X, Li J, Lu D, Wei X, Xu X. Advances in multi-omics research on viral hepatitis. *Front Microbiol*. 2022;13:923596.
26. Thiele M, Villesen IF, Niu L, Johansen S, Sulek K, Nishijima S, et al. Opportunities and barriers in omics-based biomarker discovery for liver diseases. *J Hepatol*. 2024;81(2):345-359.
27. Xia X, Ghosh S, Richards D, et al. The integration of multi-omics with artificial intelligence in hepatology: a comprehensive review of personalized medicine, biomarker identification, and drug discovery. *J Clin Exp Hepatol*. 2025;15(6):102611.
28. Morel SMG, Wu S, Kendall TJ, Guha IN, Fallowfield JA, et al. Artificial intelligence applied to omics data in liver disease: towards a personalised approach for diagnosis, prognosis and treatment. *J Hepatol*. 2024;81(5):1015-1032.
29. Zhang Y, et al. Advances in multi-omics applications in HBV-associated hepatocellular carcinoma. *Front Immunol*. 2021;12:754244.

30. Krause J, Schramm C. Multi-omics characterization of healthy and PSC human liver—what we knew and what we have learned. *J Hepatol*. 2024.
31. Liu H, et al. Epigenetic modification of hepatitis B virus infection and related hepatocellular carcinoma. *Virulence*. 2024;15(1):2421231.
32. Peng N, Song SJ, Hui VWK, Lai JCT, Wong GLH, Wong VWS, et al. Foundations of artificial intelligence in hepatology: what a clinician needs to know. *J Clin Exp Hepatol*. 2026;16(1):103183. doi:10.1016/j.jceh.2025.103183.
33. Spann A, Strauss AT, Davis SE, Bhat M. The role of artificial intelligence in chronic liver diseases and liver transplantation. *Gastroenterology*. 2025;169(2):456-470.
34. Shin H, Hur MH, Song BG, et al. AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B. *J Hepatol*. 2025;82:1080-1088.
35. Abdurrachim D, Lek S, Ong CZL, et al. Utility of AI digital pathology as an aid for pathologists scoring fibrosis in metabolic dysfunction-associated steatotic hepatitis. *J Hepatol*. 2025;82:898-908.
36. Eskandar K. Artificial intelligence in hepatology: a comprehensive scoping review of clinical applications, challenges, and future directions. *iLIVER*. 2025;4(4):100205. doi:10.1016/j.iliver.2025.100205.
37. Malik S, Das R, Thongtan T, et al. AI in hepatology: revolutionizing the diagnosis and management of liver disease. *J Clin Med*. 2024;13(24):7833.
38. Zhou T. Optimizing clinical adoption of large language models in hepatology: toward terminological precision, multilingual adaptability, and interpretive literacy. *J Hepatol*. 2025. doi:10.1016/j.jhep.2025.08.034.
39. Morel SMG, Wu S, Kendall TJ, Guha IN, Fallowfield JA, et al. Opportunities and challenges of artificial intelligence in hepatology. *npj Gut Liver*. 2026;3:3.
40. Morel SMG, Jones RP, Fallowfield JA, et al. The barriers to uptake of artificial intelligence in hepatology and how to overcome them. *J Hepatol*. 2025. doi:10.1016/j.jhep.2025.07.003.
41. Suenghataiphorn T, Tribuddharat N, Danpanichkul P, Kulthamrongsri N. Large language models in hepatology: a systematic review. *Hepatol Forum*. 2026.
42. Nature Reviews Gastroenterology & Hepatology. Large language models for clinical decision support in gastroenterology and hepatology. *Nat Rev Gastroenterol Hepatol*. 2025.
43. Katsoulakis E, Wang Q, Wu H, Shahriyari L, Fletcher R, Liu J, et al. Digital twins for health: a scoping review. *npj Digit Med*. 2024;7:77.
44. Shen M, Chen S, Ding X. The effectiveness of digital twins in promoting precision health across the entire population: a systematic review. *npj Digit Med*. 2024;7:145.
45. Zhang K, Zhou HY, Baptista-Hon DT, Gao Y, Liu X, Oermann E, et al. Concepts and applications of digital twins in healthcare and medicine. *Patterns*. 2024;5(8):101028.

46. Johnson B, Curtius K. Digital twins are integral to personalizing medicine and improving public health. *Nat Rev Gastroenterol Hepatol*. 2024;21:740-741.
47. Laubenbacher R, Mehrad B, Shmulevich I, Trayanova N, et al. Digital twins in medicine. *Nat Comput Sci*. 2024;4:184-191.
48. Lin B, Ma Y, Wu S. Multi-omics and artificial intelligence-guided data integration in chronic liver disease: prospects and challenges for precision medicine. *OMICS*. 2022;26(8):431-443. doi:10.1089/omi.2022.0079.
49. Ansari HR, Rehan M, Ahmed F. AI in multi-omics analysis of liver diseases. *Prog Mol Biol Transl Sci*. 2026;222:241-259. doi:10.1016/bs.pmbts.2026.02.004.
50. Pinu FR, Beale DJ, Paten AM, Kouremenos K, Swarup S, Schirra HJ, Wishart D. Systems biology and multi-omics integration: viewpoints from the metabolomics research community. *Metabolites*. 2019;9(4):76.
51. Wu Y, Xie L. AI-driven multi-omics integration for multi-scale predictive modeling of genotype-environment-phenotype relationships. *Comput Struct Biotechnol J*. 2025;27:265-277.
52. Liu F, Beck S, Yang L, et al. Advancing AI for multi-omics and clinical data integration in basic and translational cancer research. *Nat Rev Cancer*. 2026;26:497-512.
53. Hsu CY, Askar S, Alshkarchy SS, et al. AI-driven multi-omics integration in precision oncology: bridging the data deluge to clinical decisions. *Clin Exp Med*. 2026;26:29.
54. Wang Y, Zhang L, Chen H, et al. Multi-model applications and cutting-edge advancements of artificial intelligence in hepatology in the era of precision medicine. *Hepatobiliary Pancreat Dis Int*. 2025.
55. Wiens J, Saria S, Sendak M, et al. Do no harm: a roadmap for responsible machine learning for health care. *Nat Med*. 2019;25(9):1337-1340.
56. Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key challenges for delivering clinical impact with artificial intelligence. *BMC Med*. 2019;17:195.
57. Collins GS, Moons KGM. Reporting of artificial intelligence prediction models in healthcare. *BMJ*. 2019;365:l1286.
58. Beam AL, Kohane IS. Big data and machine learning in health care. *JAMA*. 2018;319(13):1317-1318.
59. Rieke N, Hancox J, Li W, et al. The future of digital health with federated learning. *npj Digit Med*. 2020;3:119.
60. Vayena E, Blasimme A, Cohen IG. Machine learning in medicine: addressing ethical challenges. *PLoS Med*. 2018;15(11):e1002689.
61. Moor M, Banerjee O, Abad ZSH, et al. Foundation models for generalist medical artificial intelligence. *Nature*. 2023;616(7956):259-265.
62. Kamel Boulos MN, Zhang P. Digital twins: from personalised medicine to precision public health. *J Pers Med*. 2021;11(8):745.

63. Singhal K, Azizi S, Tu T, et al. Large language models encode clinical knowledge. *Nature*. 2023;620(7972):172-180.
64. Khoury MJ, Ioannidis JPA. Medicine and public health in the era of big data and precision medicine. *Genet Med*. 2014;16(10):739-741.